Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis E Tacconelli, E Carrara, A Savoldi, S Harbarth, M Mendelson, DL Monnet, ... The Lancet infectious diseases 18 (3), 318-327, 2018 | 5169 | 2018 |
The global preclinical antibacterial pipeline U Theuretzbacher, K Outterson, A Engel, A Karlén Nature Reviews Microbiology 18 (5), 275-285, 2020 | 592 | 2020 |
Antibiotic development—economic, regulatory and societal challenges C Årdal, M Balasegaram, R Laxminarayan, D McAdams, K Outterson, ... Nature Reviews Microbiology 18 (5), 267-274, 2020 | 333 | 2020 |
Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets K Outterson Yale J. Health Pol’y L. & Ethics 5, 193, 197, 2005 | 262 | 2005 |
The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later R Laxminarayan, T Van Boeckel, I Frost, S Kariuki, EA Khan, ... The Lancet Infectious Diseases 20 (4), e51-e60, 2020 | 245 | 2020 |
International cooperation to improve access to and sustain effectiveness of antimicrobials C Årdal, K Outterson, SJ Hoffman, A Ghafur, M Sharland, N Ranganathan, ... The Lancet 387 (10015), 296-307, 2016 | 181 | 2016 |
An international legal framework to address antimicrobial resistance SJ Hoffman, K Outterson, JA Røttingen, O Cars, C Clift, Z Rizvi, F Rotberg, ... Bulletin of the World Health Organization 93, 66-66, 2015 | 139 | 2015 |
The ethics of poverty tourism E Selinger, K Outterson Boston University School of Law Working Paper, 2009 | 137* | 2009 |
Plunging into Endless Difficulties: Medicaid and Coercion in National Federation of Independent Business v. Sebelius N Huberfeld, EW Leonard, K Outterson BUL Rev. 93, 1, 2013 | 131* | 2013 |
Progress in the fight against multidrug-resistant bacteria? A review of US Food and Drug Administration–approved antibiotics, 2010–2015 D Deak, K Outterson, JH Powers, AS Kesselheim Annals of internal medicine 165 (5), 363-372, 2016 | 120 | 2016 |
Antibiotic research and development: business as usual? S Harbarth, U Theuretzbacher, J Hackett, Drive-AB Consortium, ... Journal of Antimicrobial Chemotherapy 70 (6), 1604-1607, 2015 | 117 | 2015 |
Repairing the broken market for antibiotic innovation K Outterson, JH Powers, GW Daniel, MB McClellan Health affairs 34 (2), 277-285, 2015 | 109 | 2015 |
Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward AK Nanayakkara, HW Boucher, VG Fowler Jr, A Jezek, K Outterson, ... CA: a cancer journal for clinicians 71 (6), 488-504, 2021 | 106 | 2021 |
Towards new business models for R&D for novel antibiotics AD So, N Gupta, SK Brahmachari, I Chopra, B Munos, C Nathan, ... Drug Resistance Updates, 2011 | 103 | 2011 |
Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Intellectual Property Law, The K Outterson U. Pitt. L. Rev. 67, 67, 2005 | 91 | 2005 |
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach JH Rex, K Outterson The Lancet Infectious Diseases 16 (4), 500-505, 2016 | 90 | 2016 |
What will it take to address the global threat of antibiotic resistance? SJ Hoffman, K Outterson Journal of Law, Medicine & Ethics 43 (S3), 6-11, 2015 | 89 | 2015 |
Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals AS Kesselheim, K Outterson Health Affairs 29 (9), 1689-1696, 2010 | 87 | 2010 |
Will longer antimicrobial patents improve global public health? K Outterson, JB Samora, K Keller-Cuda The Lancet infectious diseases 7 (8), 559-566, 2007 | 82 | 2007 |
Patent buy-outs for global disease innovations for low-and middle-income countries K Outterson Am. JL & Med. 32, 159, 2006 | 80 | 2006 |